๐Ÿงช NEW DRUG DEVELOPMENT AND PRECLINICAL TOXICITY STUDIES

By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD 

๐ŸŒ INTRODUCTION: WHY STUDY DRUGS BEFORE HUMAN USE?

Before a new drug is tested in humans, it must undergo preclinical studies in laboratory animals. These studies are done to:

  • Establish scientific rationale for safety

  • Determine safe dose ranges and routes of administration

  • Predict potential toxicities and side effects in humans

  • Comply with regulatory and ethical standards (GCP, GLP, CPCSEA/CCSEA guidelines in India)

⚖️ The ultimate goal: Protect human participants when clinical trials begin.


๐Ÿ”‘ TYPES OF PRECLINICAL TOXICITY STUDIES

General Rule: Preclinical toxicity testing must be done in two animal species — one rodent (rat/mouse) and one non-rodent (dog/monkey), using the intended human route (oral, IV, inhalation, etc.).


1. Acute Toxicity Studies

  • Purpose: To determine LD₅₀ (median lethal dose) and identify immediate toxic effects.

  • Method:

    • Animals receive a single dose or graded doses.

    • Monitored for 24–72 hours for mortality and clinical signs.

  • Outcome: Defines the safety margin and helps select the starting human dose (usually 1/100th of LD₅₀ in animals).

  • Example: A drug with LD₅₀ = 200 mg/kg in rats → starting human dose ≈ 2 mg/kg.


2. Subacute (Repeated-Dose) Toxicity Studies

  • Purpose: Detect cumulative toxicity and target organ damage.

  • Duration: 14–28 days.

  • Parameters Monitored:

    • Body weight, food/water intake

    • Hematology (Hb, WBCs), Biochemistry (liver enzymes, kidney function)

    • Histopathology of vital organs (liver, kidney, heart, lungs, etc.)

  • Outcome: Establishes:

    • Maximum Tolerated Dose (MTD)

    • No Observed Adverse Effect Level (NOAEL)

  • Clinical Tip: If hepatotoxicity appears in rats, then LFTs are monitored closely in Phase I human trials.


3. Chronic Toxicity Studies

  • Purpose: Assess long-term safety and simulate chronic human use.

  • Duration: 6–12 months (sometimes longer depending on intended therapy).

  • Animals: One rodent + one non-rodent species.

  • Monitoring: Same as subacute, but with more focus on:

    • Organ damage

    • Carcinogenic potential

    • Cumulative effects of repeated dosing

  • Example: Chronic NSAID exposure → renal papillary necrosis in animals → routine renal monitoring in patients.


4. Special Toxicity Studies

These assess genetic, reproductive, and developmental risks:

TypePurposeCommon Tests
MutagenicityDNA mutations & chromosomal damageAmes test, chromosomal assays
CarcinogenicityDetect cancer-causing potential2-year rodent studies
TeratogenicityFetal malformations (birth defects)Administered to pregnant animals
Reproductive ToxicityFertility, pregnancy, lactation effectsPre-mating to lactation studies

⚠️ Clinical Application: The thalidomide tragedy (causing birth defects) → made teratogenicity testing mandatory worldwide.


๐Ÿ“Š HOW THESE STUDIES GUIDE HUMAN TRIALS

Study TypeHuman Application
Acute ToxicitySets initial human dose and emergency safety guidelines
Subacute ToxicityDefines short-term therapeutic window
Chronic ToxicityEssential for chronic diseases (HTN, diabetes, epilepsy)
Special ToxicityGuides use in pregnancy, pediatrics, cancer therapy

⚖️ REGULATORY & ETHICAL FRAMEWORK (INDIA)

  • Preclinical studies must follow Good Laboratory Practice (GLP).

  • Ethical oversight by CCSEA (formerly CPCSEA – Committee for the Control and Supervision of Experiments on Animals), Ministry of Environment, Forest & Climate Change, Govt. of India.

  • Mandatory approvals before starting:

    • Institutional Animal Ethics Committee (IAEC) approval

    • CCSEA registration of animal house

  • Only after preclinical package (toxicity + pharmacology) is complete → IND (Investigational New Drug) application is submitted to DCGI (CDSCO) for human trials.


๐Ÿ“ SUMMARY

  • Preclinical toxicity studies are mandatory before clinical trials.

  • Include acute, subacute, chronic, and special tests in at least two animal species.

  • Outcomes: MTD, NOAEL, organ-specific risks.

  • Guide dose selection, patient monitoring, and trial design.

  • Governed by GLP, IAEC, and CCSEA regulations in India



๐Ÿ“˜ Prepared by Dr. Sk Sabir Rahaman
๐Ÿ“ Specialist Family Physician | Consultant Pharmacologist | Lifestyle & Diabetes Expert

๐ŸŒ Visit My Website for  Articles & other Free PDFs and Resources

Comments

Popular posts from this blog

๐Ÿฅ Insulin Storage: Myths vs. Facts Every Diabetic Should Know

๐Ÿงด TREATMENT OF POISONING – A COMPREHENSIVE OVERVIEW

๐ŸŒฟ Rational Use of Medicines (RUM): A Guide for Safer and Smarter Prescribing